GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (NAS:KALV) » Definitions » Operating Income

KALV (KalVista Pharmaceuticals) Operating Income : $-172.97 Mil (TTM As of Jan. 2025)


View and export this data going back to 2015. Start your Free Trial

What is KalVista Pharmaceuticals Operating Income?

KalVista Pharmaceuticals's Operating Income for the three months ended in Jan. 2025 was $-42.94 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2025 was $-172.97 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. KalVista Pharmaceuticals's Operating Income for the three months ended in Jan. 2025 was $-42.94 Mil. KalVista Pharmaceuticals's Revenue for the three months ended in Jan. 2025 was $0.00 Mil. Therefore, KalVista Pharmaceuticals's Operating Margin % for the quarter that ended in Jan. 2025 was %.

KalVista Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. KalVista Pharmaceuticals's annualized ROC % for the quarter that ended in Jan. 2025 was -1,025.57%. KalVista Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 was -2,187.34%.


KalVista Pharmaceuticals Operating Income Historical Data

The historical data trend for KalVista Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Operating Income Chart

KalVista Pharmaceuticals Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.53 -57.92 -81.31 -95.09 -131.99

KalVista Pharmaceuticals Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.15 -40.00 -44.22 -45.81 -42.94

KalVista Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-172.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KalVista Pharmaceuticals  (NAS:KALV) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

KalVista Pharmaceuticals's annualized ROC % for the quarter that ended in Jan. 2025 is calculated as:

ROC % (Q: Jan. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2024 ) + Invested Capital (Q: Jan. 2025 ))/ count )
=-171.76 * ( 1 - -9.6% )/( (17.079 + 19.632)/ 2 )
=-188.24896/18.3555
=-1,025.57 %

where

Invested Capital(Q: Oct. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=160.831 - 13.649 - ( 135.776 - max(0, 22.164 - 152.267+135.776))
=17.079

Invested Capital(Q: Jan. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=275.993 - 14.617 - ( 253.203 - max(0, 25.615 - 267.359+253.203))
=19.632

Note: The Operating Income data used here is four times the quarterly (Jan. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

KalVista Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2024  Q: Jan. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-165.68/( ( (7.902 + max(-17.064, 0)) + (7.247 + max(-19.417, 0)) )/ 2 )
=-165.68/( ( 7.902 + 7.247 )/ 2 )
=-165.68/7.5745
=-2,187.34 %

where Working Capital is:

Working Capital(Q: Oct. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.563) - (13.649 + 0 + 6.978)
=-17.064

Working Capital(Q: Jan. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.754) - (14.617 + 0 + 9.554)
=-19.417

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

KalVista Pharmaceuticals's Operating Margin % for the quarter that ended in Jan. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2025 )/Revenue (Q: Jan. 2025 )
=-42.94/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


KalVista Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Executives
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Benjamin L Palleiko officer: CFO and Secretary C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139
Paul K. Audhya officer: Chief Medical Officer C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Christopher Yea officer: Chief Development Officer ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Edward P. Feener officer: Chief Scientific Officer ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Thomas Andrew Crockett director, officer: President and CEO BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ
Albert Cha director 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Patrick Treanor director C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Michael David Smith officer: Senior VP, Development C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Andreas Maetzel officer: Senior Vice President Medical 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Nancy Stuart director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Brian Jg Pereira director C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138
Daniel B Soland director 4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Sv Life Sciences Fund Iv (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108